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Rationale: Chronic Granulomatous Disease (CGD) is an inherited primary 
immunodeficiency disorder caused by defective components of the NADPH oxidase. CGD 
patients are susceptible to severe and recurrent infections. We propose to use a lentiviral 
gene therapy strategy to restore the expression of the p47-phox NADPH oxidase component, 
coded by the NCF1 gene. Mutations in p47-phox cause the second most common form of 
CGD. 
Methods: We have made a lentiviral vector, pCCLChimp47-phox, that contains the chimeric 
cathepsin G/c-fes myeloid promoter and a codon optimized version of the human p47-phox 
gene. We have introduced the lentiviral vector in a myeloid leukemia cell line deficient for 
p47-phox, in primary monocytes-derived macrophages taken from p47-phox CGD patients and 
in a mouse model of p47-phox CGD. 
Results: The lentiviral gene therapy efficiently restores p47-phox expression and NAPDH 
oxidase function in all models tested. Notedly, p47-phox-/- mice transplanted with gene 
therapy treated stem cells (bearing ~1 copy of vector) recovered an average of ~85%  
functional granulocytes with levels of oxidase activity comparable to wild type. 
Conclusions: Overall our study shows that the pCCLChimp47-phox vector is a promising tool 
for the clinical application of p47-phox CGD gene therapy. 
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